Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes on stomach cancer in first human trial

NCT ID NCT06056024

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shrink tumors. The study is now complete and no longer enrolling new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BI 3706674 (a tablet that blocks growth signals in cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced stomach or esophageal cancer that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 47 participants, so it is not yet clear if the drug is effective or safe for a larger population. Side effects are unknown and the drug is being tested in humans for the first time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, KRAS MUTATION

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, 135-8550, Japan

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic-Arizona

    Phoenix, Arizona, 85054, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • NCKUH

    Tainan, 704, Taiwan

  • National Cancer Center Hospital East

    Chiba, Kashiwa, 277-8577, Japan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • The Catholic University of Korea, Seoul St.Mary's Hospital

    Seoul, 137-701, South Korea

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.